As part of Canada’s Biomanufacturing and Life Sciences Strategy (BLSS), the Canadian Institutes of Health Research (CIHR) Clinical Trials Fund (CTF) will be foundational in ensuring that Canadians are well served by a national clinical trials network that fosters all aspects of therapeutics development, from discovery through to delivery. Approximately $60M is being awarded to 22 projects to fund clinical trial phases, designs, and objectives that align with the priorities of the BLSS.
The Canadian Nephrology Trials Network is pleased to announce we were included in a successful CIHR grant application for the The Accelerating Clinical Trials Consortium. CNTN member will be involved in committees moving forward and we are excited to be part of this work and to help accelerate clinical trials in Canada
The Canadian Nephrology Trials Network would like to acknowledge and congratulate their funding partner Can-SOLVE CKD Network on Phase 2 funding announcement. Can-SOLVE CKD will receive $3.75 million in new funding from CIHR matched by more than $8 million raised through the generous support of more than 60 partners.
The CNTN is thrilled about the investment being made by CIHR and Can-SOLVE CKD’s partner funders. Our organization is excited to continue our work towards improving the design, implementation and delivery of nephrology clinical trials in Canada.
CNTN Executive Co-Chairs Karthik Tennankore, François Madore, Hans Vorster, Dwight Sparkes
Can-SOLVE CKD Phase 2 is focused on mobilizing the findings of projects launched during the network’s first five years. Read the full network statement here:
Nominated Principal Investigators receiving CIHR grant funds for clinical trial research on or after January 1, 2022 must comply with the following practices to remain eligible for new CIHR funding:
Clinical trials must be registered in a publicly available, free-to-access, searchable clinical trial registry complying with the WHO’s international agreed standards before the researcher meets with the first study participant.
New Public disclosure of results must be done within a mandated time frame:
Publications describing clinical trial results must be open access from the date of publication.
Summary results must be publicly available within 12 months from the last visit of the last participant (for collection of data on the primary outcome).
New All study publications must include the registration number/Trial ID (to be specified in the article summary/abstract).